Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Tafenoquine: a promising new antimalarial agent.

Crockett M, Kain KC.

Expert Opin Investig Drugs. 2007 May;16(5):705-15. Review.

PMID:
17461742
2.

Tafenoquine: First Global Approval.

Frampton JE.

Drugs. 2018 Sep;78(14):1517-1523. doi: 10.1007/s40265-018-0979-2. Review.

PMID:
30229442
3.

Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria.

Walsh DS, Eamsila C, Sasiprapha T, Sangkharomya S, Khaewsathien P, Supakalin P, Tang DB, Jarasrumgsichol P, Cherdchu C, Edstein MD, Rieckmann KH, Brewer TG.

J Infect Dis. 2004 Oct 15;190(8):1456-63. Epub 2004 Sep 20.

PMID:
15378438
4.

Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.

Watson J, Taylor WRJ, Bancone G, Chu CS, Jittamala P, White NJ.

PLoS Negl Trop Dis. 2018 Apr 20;12(4):e0006440. doi: 10.1371/journal.pntd.0006440. eCollection 2018 Apr.

5.

Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.

Ebstie YA, Abay SM, Tadesse WT, Ejigu DA.

Drug Des Devel Ther. 2016 Jul 26;10:2387-99. doi: 10.2147/DDDT.S61443. eCollection 2016. Review.

6.

Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.

Edstein MD, Walsh DS, Eamsila C, Sasiprapha T, Nasveld PE, Kitchener S, Rieckmann KH.

Med Trop (Mars). 2001;61(1):56-8. Review.

PMID:
11584657
7.

Tafenoquine for travelers' malaria: evidence, rationale and recommendations.

Baird JK.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay110.

8.

A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum.

Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, Prescott WR, Baird JK, Nkrumah F, Ritchie TL, Franke ED, Binka FN, Horton J, Hoffman SL.

Clin Infect Dis. 2003 Mar 1;36(5):541-9. Epub 2003 Feb 14.

PMID:
12594633
9.

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.

Llanos-Cuentas A, Lacerda MVG, Hien TT, Vélez ID, Namaik-Larp C, Chu CS, Villegas MF, Val F, Monteiro WM, Brito MAM, Costa MRF, Chuquiyauri R, Casapía M, Nguyen CH, Aruachan S, Papwijitsil R, Nosten FH, Bancone G, Angus B, Duparc S, Craig G, Rousell VM, Jones SW, Hardaker E, Clover DD, Kendall L, Mohamed K, Koh GCKW, Wilches VM, Breton JJ, Green JA.

N Engl J Med. 2019 Jan 17;380(3):229-241. doi: 10.1056/NEJMoa1802537.

10.

Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.

Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, Yilma D, Batista Pereira D, Espino FEJ, Mia RZ, Chuquiyauri R, Val F, Casapía M, Monteiro WM, Brito MAM, Costa MRF, Buathong N, Noedl H, Diro E, Getie S, Wubie KM, Abdissa A, Zeynudin A, Abebe C, Tada MS, Brand F, Beck HP, Angus B, Duparc S, Kleim JP, Kellam LM, Rousell VM, Jones SW, Hardaker E, Mohamed K, Clover DD, Fletcher K, Breton JJ, Ugwuegbulam CO, Green JA, Koh GCKW.

N Engl J Med. 2019 Jan 17;380(3):215-228. doi: 10.1056/NEJMoa1710775.

11.

Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.

Rajapakse S, Rodrigo C, Fernando SD.

Cochrane Database Syst Rev. 2015 Apr 29;(4):CD010458. doi: 10.1002/14651858.CD010458.pub2. Review.

12.
13.

A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria.

Shanks GD, Oloo AJ, Aleman GM, Ohrt C, Klotz FW, Braitman D, Horton J, Brueckner R.

Clin Infect Dis. 2001 Dec 15;33(12):1968-74. Epub 2001 Nov 7.

PMID:
11700577
14.

Tafenoquine receives regulatory approval in USA for prophylaxis of malaria and radical cure of Plasmodium vivax.

Tan KR, Hwang J.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay071. No abstract available.

PMID:
30137454
15.

Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.

Kitchener S, Nasveld P, Edstein MD.

Am J Trop Med Hyg. 2007 Mar;76(3):494-6.

PMID:
17360873
16.

Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers.

Edstein MD, Kocisko DA, Brewer TG, Walsh DS, Eamsila C, Charles BG.

Br J Clin Pharmacol. 2001 Dec;52(6):663-70.

17.

Malaria chemoprophylaxis with tafenoquine: a randomised study.

Lell B, Faucher JF, Missinou MA, Borrmann S, Dangelmaier O, Horton J, Kremsner PG.

Lancet. 2000 Jun 10;355(9220):2041-5.

PMID:
10885356
18.

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.

Walsh DS, Wilairatana P, Tang DB, Heppner DG Jr, Brewer TG, Krudsood S, Silachamroon U, Phumratanaprapin W, Siriyanonda D, Looareesuwan S.

Clin Infect Dis. 2004 Oct 15;39(8):1095-103. Epub 2004 Sep 24.

PMID:
15486831
19.

Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand.

Walsh DS, Looareesuwan S, Wilairatana P, Heppner DG Jr, Tang DB, Brewer TG, Chokejindachai W, Viriyavejakul P, Kyle DE, Milhous WK, Schuster BG, Horton J, Braitman DJ, Brueckner RP.

J Infect Dis. 1999 Oct;180(4):1282-7.

PMID:
10479159
20.

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.

Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Möhrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L.

Lancet. 2014 Mar 22;383(9922):1049-58. doi: 10.1016/S0140-6736(13)62568-4. Epub 2013 Dec 19.

PMID:
24360369

Supplemental Content

Support Center